Melanoma Clinical Trials

91 studies are recruiting for melanoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 4

1. A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

   This is a noninterventional, observational, long-term follow-up (LTFU) study. Patients in this study will be followed for 5 years from enrollment on this study to assess potential delayed risks of RPx products. Eligible participants for this LTFU study include patients who received at least 1 dose …

   Stage

   Not phased

   Ages

   18 and older

   Site

   UC San Diego Moores Cancer Center, La Jolla, California

   Locations

   2 in total

   Run by

   Replimune, Inc.

   See if you can join NCT06887348 on ClinicalTrials.gov

2. Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

   This study will evaluate how safe the study drug is, how well patients tolerate it, how it works in the body, and the disease's response to the drug. The study drug being tested is sarilumab, when given with the combination of ipilimumab, nivolumab, and relatlimab in patients like yourself, with st…

   Stage

   Phase 2

   Ages

   18 to 100

   Site

   The Angeles Clinic at Cedars Sinai, Los Angeles, California

   Locations

   4 in total

   Run by

   NYU Langone Health

   See if you can join NCT05428007 on ClinicalTrials.gov

3. Molecular Analysis of Childhood and Adolescent Melanocytic Lesions

   This is an observational, non-therapeutic study to collect clinical and molecular information of pediatric patients with childhood melanocytic lesions. PRIMARY OBJECTIVE: To perform a comprehensive molecular analysis of samples either from paraffin embedded and/or frozen tissue from patients with p…

   Stage

   Not phased

   Ages

   Up to 18

   Site

   St. Jude Children's Research Hospital, Memphis, Tennessee

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT02775643 on ClinicalTrials.gov

4. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Birmingham, Alabama

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov

5. A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

   This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   9 in total

   Run by

   ImmVira Pharma Co. Ltd

   See if you can join NCT04370587 on ClinicalTrials.gov

6. Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment

   The purpose of this research is to identify biological characteristics occurring in the initiation and progression of melanoma.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Vanderbitl-Ingram Cancer Center, Nashville, Tennessee

   Run by

   Vanderbilt-Ingram Cancer Center

   See if you can join NCT01205815 on ClinicalTrials.gov

7. Excision of Lymph Node Trial (EXCILYNT) (Mel69)

   The purpose of this study is to find out if removing only the cancerous lymph node (known as a lymph node excision) is effective at preventing cancer from coming back in the same area of the lymph node excision. The study team is also trying to find out the side effects of this type of surgery and …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Emory University, Atlanta, Georgia

   Locations

   7 in total

   Run by

   Craig L Slingluff, Jr

   See if you can join NCT05839912 on ClinicalTrials.gov

8. In Vivo Liquid Biopsy of Melanoma (Cytophone)

   The Cytophone is a first in the world patented system to identify and count single circulating melanoma cells in blood circulation inside the human body. The Cytophone has a unique capability to find rare melanoma cells in the blood by an assessment of 100-500 times greater amounts of blood volume …

   Stage

   Not phased

   Ages

   18 to 80

   Site

   SSM Health Dean Medical Group Specialty Services, Madison, Wisconsin

   Run by

   Cytoastra

   See if you can join NCT06488365 on ClinicalTrials.gov

9. BostonGene and Exigent Genomic INsight Study

   The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Highlands Oncology Group, Rogers, Arkansas

   Locations

   7 in total

   Run by

   BostonGene

   See if you can join NCT06272864 on ClinicalTrials.gov

10. Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

    Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of advanced or metastatic cancer. The proposed study intends to address the un…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, Irvine, Irvine, California

    Locations

    4 in total

    Run by

    CJ Bioscience, Inc.

    See if you can join NCT05877430 on ClinicalTrials.gov

11. A Study of IBI363 in Subjects with Advanced Solid Malignancies

    This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California, San Francisco (UCSF), San Francisco, California

    Locations

    9 in total

    Run by

    Innovent Biologics (Suzhou) Co. Ltd.

    See if you can join NCT06281678 on ClinicalTrials.gov

12. Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

    This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab [Gazyva®] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monotherapy arm is also planned;…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    HonorHealth Research Institute, Scottsdale, Arizona

    Locations

    6 in total

    Run by

    Simcha IL-18, Inc.

    See if you can join NCT04787042 on ClinicalTrials.gov

13. Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

    This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indicat…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Yale, New Haven, Connecticut

    Locations

    15 in total

    Run by

    IO Biotech

    See if you can join NCT05280314 on ClinicalTrials.gov

14. A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

    A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination with Pembrolizumab in Subjects with Locally Advanced/Metastatic Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, Dallas, Dallas, Texas

    Locations

    2 in total

    Run by

    Hefei TG ImmunoPharma Co., Ltd.

    See if you can join NCT05746897 on ClinicalTrials.gov

15. A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

    The main purpose of this study is to evaluate the safety of Vemurafenib in combination with Metformin in melanoma patients. The phase II part of the study will also evaluate the clinical activity of the combined regiment. Based on pre-clinical studies and a phase I trial, the investigators hypothes…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    James Graham Brown Cancer Center-University of Louisville, Louisville, Kentucky

    Run by

    University of Louisville

    See if you can join NCT01638676 on ClinicalTrials.gov

16. Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

    Phase I clinical trial to determine the Phase II dose of autologous TIL 1383I TCR gene modified T Cells using a retrovirus. This is a novel National Cancer Institute (NCI) funded investigator initiated therapy for patients with advanced melanoma.

    Stage

    Phase 1

    Ages

    18 to 89

    Site

    Loyola University Medical Center, Maywood, Illinois

    Run by

    Loyola University

    See if you can join NCT02870244 on ClinicalTrials.gov